#Tirzepatide, a dual GLP-1 and GIP receptor agonist, is FDA-approved (as Zepbound) for weight loss in obese/overweight individuals. It reduces appetite, slows gastric emptying, and enhances insulin sensitivity, leading to significant weight loss.

Tirzepatide clinical trials demonstrate significant weight loss with Tirzepatide. In SURMOUNT-1, participants achieved up to 20.9% weight loss over 72 weeks, with early data suggesting 5-6% weight loss in the first 6 weeks, based on reports like "It takes time, about 8 to 12 weeks to see a 6% to 8% weight loss in adults using Mounjaro" from Drugs.com. 

                                                                                               Figure 1: Tirzepatide injection

#Ketogenic diets (KDs) that elevate beta-hydroxybutyrate (#BHB) promote weight and fat loss.

And, a plausible approach to support muscle anabolism during a hypocaloric KD is the use of exogenous ketone salts (KS), which enhance ketosis while also providing additional sodium and potentially other minerals (e.g., potassium, calcium, magnesium). Oral ingestion of #ketone salts consisting of beta-hydroxybutyrate (BHB) and minerals is a safe and effective method of transiently increasing circulating ketones as we and others have shown.

The KD clinical data of firgue 2 showed that its about 7-8 kg weight loss after 6 weeks.

                                                                                           Figure 2: Ketogenic diets